Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Florquinitau F18 - Lantheus Cerveau

Next Previous
Drug Profile

Florquinitau F18 - Lantheus Cerveau

Alternative Names: [18F]MK 6240; [18F]MNI-946; [F-18]MK-6240; Fluorine 18 MK 6240 - Lantheus Cerveau; Fluorine-18-MK6240; MK-6240; MK-6240 SUVR; XTR006

Latest Information Update: 06 Nov 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cerveau Technologies; Merck Sharp & Dohme
  • Developer Enigma Biomedical group; Johnson & Johnson Innovative Medicine; Lantheus Cerveau; Merck Sharp & Dohme; Sinotau Pharmaceuticals; Washington University School of Medicine
  • Class Amines; Diagnostic agents; Imaging agents; Isoquinolines; Pyridines; Pyrroles; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Alzheimer's disease
  • Phase II Neurodegenerative disorders

Most Recent Events

  • 28 Oct 2025 Preregistration for Alzheimer's disease (Diagnosis) in USA (IV)
  • 28 Oct 2025 Florquinitau F18 - Lantheus Cerveau receives Fast Track designation for Alzheimer's disease [IV,Injection] (Diagnosis) in USA prior to October 2025
  • 28 Oct 2025 US FDA assigns PDUFA action date of 13/08/2026 for Florquinitau F18 for Alzheimer's disease (Diagnosis)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top